Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer - a podcast by Clinical Care Options
from 2021-04-28T20:15
::
::
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Key data supporting the clinical use of these agents
- Optimal sequencing and timing of use
- Dosing considerations
- Key adverse events
Presenters:
Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program: BITLY NEEDED
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options